Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3839056 · 1 trial · 1 indication
Frequency of AEs, TEAEs, SAEs, and Discontinuation due to TEAEs.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 IV | EXPERIMENTAL | Participants will receive LY3839056 Intravenously |
| Cohort 2 IV | EXPERIMENTAL | Participants will receive LY3839056 Intravenously |
| Cohort 3 IV | EXPERIMENTAL | Participants will receive LY3839056 Intravenously |
| Cohort 4a IV | EXPERIMENTAL | Participants will receive LY3839056 Intravenously |
| Cohort 4b SC | EXPERIMENTAL | Participants will receive LY3839056 Subcutaneously |
| Cohort 5 IV | EXPERIMENTAL | Participants will receive LY3839056 Intravenously |
| Cohort 6a IV | EXPERIMENTAL | Participants will receive LY3839056 Intravenously |
| Cohort 6b SC | EXPERIMENTAL | Participants will receive LY3839056 Subcutaneously |
| Placebo IV | PLACEBO_COMPARATOR | Participants will receive Placebo Intravenously |
| Placebo SC | PLACEBO_COMPARATOR | Participants will receive Placebo Subcutaneously |
| Name | Type | Description |
|---|---|---|
| LY3839056 IV | DRUG | LY3839056 Administered Intravenously |
| Placebo IV | DRUG | Placebo Administered Intravenously |
| LY3839056 SC | DRUG | LY3839056 Administered Subcutaneously |
| Placebo SC | DRUG | Placebo Administered Subcutaneously |
Key Inclusion Criteria: * Are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and Cardiac Monitoring. * Have clinical laboratory test results within normal reference range for the population or the clinical research site, or re...